Teva Recalls Losartan Potassium Tablets Due to Impurity Detection
Teva Pharmaceuticals is recalling Losartan Potassium 100 mg tablets because an impurity was detected in the active ingredient.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The FDA classified this as a Class II recall. Per the rubric, FDA Class II recalls involving significant health risks or potential for serious injury are categorized as Severe (Score 4), particularly when specific impurities like NMBA are involved.
Plain-English summary
Teva Pharmaceuticals USA is recalling Losartan Potassium 100 mg tablets (NDC 00591-3747-00) in 90-count bottles. The recall involves 2,943,000 tablets distributed nationwide through four major distributors. The specific lots affected include bulk product lots 1163892A, 1163893A, 1163894A, and 1163895A, as well as finished product lots GS017042, GS017043, GS017044, and GS017541, all with an expiration date of 01/2020.
The recall was initiated due to Current Good Manufacturing Practice (CGMP) deviations. Specifically, an impurity identified as N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) was detected in the active pharmaceutical ingredient (API) used to manufacture the finished products. The FDA has classified this recall as Class II.
Consumers who have these specific lots of Losartan Potassium 100 mg tablets should stop using them and contact their healthcare provider or pharmacist for guidance on alternative treatment options. The recalled products were distributed nationwide.
The recalled product
- Product
- LOSARTAN POTASSIUM 100 mg TABLET BULK 90 count bottles, NDC 00591-3747-00
- Manufacturer
- Teva Pharmaceuticals USA
- Category
- Drug — Prescription Medication
- Affected units
- 2,943,000
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (9)
- Arrow Malta (Teva) Bulk Product Lot # 1163892A
- exp. date 01/2020 1163893A
- exp. date 01/2020 1163894A
- exp. date 01/2020 1163895A
- exp. date 01/2020 Golden State Medical Finished Product Lot # GS017042
- exp. date 01/2020 GS017043
- exp. date 01/2020 GS017044
- exp. date 01/2020 GS017541
- exp. date 01/2020
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 2 recalled by Teva Pharmaceuticals USA under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 2 products in this recall →Related recalls
Same manufacturer · Teva Pharmaceuticals USA
See all →- ModerateDoxylamine Succinate and Pyridoxine Hydrochloride Tablets Recalled for Failed Dissolution
FDA (Drugs) · 2022-02-09
- LowPrescription Drug Recall: Mimvey Mislabeling by Teva Pharmaceuticals
FDA (Drugs) · 2022-02-09
- ModerateTretinoin Capsules 10 mg Recalled for Failed Dissolution Specifications
FDA (Drugs) · 2022-02-09
- LowMimvey Estradiol/Norethindrone Prescription Drug Mislabeling Recall
FDA (Drugs) · 2022-02-09
- ModerateBrinzolamide Ophthalmic Suspension recalled for defective container caps
FDA (Drugs) · 2022-01-26
Same hazard · impurity
See all →- ModerateHikma Recalls Ramipril Capsules Due to Process Impurity
FDA (Drugs) · 2026-09-02
- ModerateMedline Remedy Specialized Silicone Cream Recalled for Elevated Formaldehyde Levels
FDA (Drugs) · 2026-07-15
- SevereCinacalcet Hydrochloride Tablets Recalled for Elevated Impurity Levels
FDA (Drugs) · 2026-07-08
- HighDuloxetine 30mg delayed-release capsules exceed nitrosamine impurity interim limit
FDA (Drugs) · 2026-06-17
- HighDuloxetine 60mg delayed-release capsules exceed nitrosamine impurity interim limit
FDA (Drugs) · 2026-06-17